Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Every year, hundreds of celebrities grace the iconic steps of the Metropolitan Museum of Art in New York City to showcase ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss ... after this time, but we ...

The increase in weight loss ... week time point in its pivotal trial. Martin Holst Lange, Novo Nordisk's head of development, said that the safety and tolerability of the two doses of semaglutide ...

WHEN Chanel Robinson piled on the pounds in the pandemic her self esteem took a hit – but that wasn’t the only downside.

A WOMAN has revealed that she lost six stone in seven months while using Mounjaro, but noticed some very strange side effects ...

In a new study, the semaglutide weight loss drug helped 2 out of 3 people ... type 2 diabetes and heart and circulatory disease. Over time, the buildup of fat in the liver can lead to inflammation ...

Moderna on Thursday pushed back the time frame for likely approval of a combination ... as it looks to stem sales of copies of its popular weight-loss drug and expand access to cash-paying patients.

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

which studied 25 milligram dose of oral semaglutide compared to placebo in 307 adults with obesity with one or more comorbidities. The company is also studying weight-loss pill amycretin ...